Core Viewpoint - The inclusion of InnoCare Pharma (09606) in the Hang Seng Composite Index and the Stock Connect program is expected to enhance its investor base and trading volume, reflecting strong market recognition of the company's performance and value [1] Group 1: Stock Performance - InnoCare Pharma's stock rose over 8% in early trading and is currently up 3.97%, priced at 418.8 HKD, with a trading volume of 133 million HKD [1] Group 2: Index Inclusion - Starting from September 8, InnoCare Pharma has officially been included in the Hang Seng Composite Index and the eligible securities for the Stock Connect program, allowing mainland Chinese investors to directly invest in its shares listed on the Hong Kong Stock Exchange [1] Group 3: Clinical Trial Update - The independent data monitoring committee (IDMC) has evaluated that the Phase III clinical trial of DB-1303/BNT323 for HER2-positive unresectable or metastatic breast cancer patients has met its primary endpoint of progression-free survival (PFS) [1] - Following the interim analysis results, the company plans to communicate with the National Medical Products Administration (NMPA) regarding the submission of the Biologics License Application (BLA) for DB-1303/BNT323 [1]
港股异动 | 映恩生物(09606)早盘涨超8% 昨日起正式进入港股通名单 HER2 ADC乳腺癌III期研究成功